FDA expands Arexvy RSV to at-risk 18–49; low uptake in 60+, new CV benefits for resp vaccines/diabetes heart push; VAX-31 Ph3 complete
Key Questions
What is the FDA's recent expansion for Arexvy RSV vaccine?
FDA expanded Arexvy to at-risk adults 18-49 on March 13, deeming it safe with rare GBS/ADEM cases. It's pending ACIP review. Uptake among 60+/75+ was 38-41% in 2024-25, varying by state (MI 61% 60-74, VI 10%).
How are RSV vaccination rates among older adults?
Uptake remains low at 38-41% for 60+/75+ in 2024-25, with researchers suggesting better access and engagement to improve rates. UK NHS rolled out RSV for 80+ from April 1, cutting hospitalizations 30-75%. US states like MO handle peds surges case-by-case without VFC extension.
What new benefits are linked to respiratory vaccines like RSV?
RSV, pneumo bundles, and Shingrix show CV, dementia, and diabetes heart risk reductions, especially for IA 50+. Studies highlight timely vaccinations for those with diabetes/heart disease. Shingles vaccines offer additional benefits beyond prevention.
What is the status of VAX-31 and RSV programs?
VAX-31 Phase 3 is complete. 48 states extended RSV peds VFC through April 30 amid spring surges, though MO did not. New programs immunize 4 in 5 children, with IFPMA noting 19x ROI.
Why focus RSV vaccines on high-risk groups?
Expansions target 18-49 at-risk due to safety data and pending ACIP. Low uptake in 60+ prompts access improvements. Benefits include reduced CV/diabetes risks, with bundles like RSV/pneumo/Shingrix aiding older adults.
Arexvy expanded Mar13 (safe, rare GBS/ADEM), uptake 38-41% 60+/75+ '24-25 (MI 61% 60-74, VI 10%); pend ACIP; RSV peds spring surge MO no VFC extend (case-by-case), 48 states thru Apr30; RSV/pneumo bundles/Shingrix cut CV/dementia/diabetes heart (IA 50+); UK NHS RSV 80+ Apr1 (30-75% hosp cut); IFPMA 19x ROI; VAX-31 Ph3 complete.